An interventional study of Sodium Bicarbonate (NaHCO3) and Placebo in AKI (Acute Kidney Injury) Due to Trauma, sponsored by Arizona State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Arizona State University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Sodium Bicarbonate in Acute Kidney Injury — 3 open to participants now, 4 under way, none of them phase 3. Sodium Bicarbonate · Acute Kidney Injury.
Among the 18 studies testing Sodium Bicarbonate in Acute Kidney Injury, this one is the 16th largest by planned enrollment, is one of 2 that started in 2026, is one of 6 with no phase, and was the 18th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →3 of the 18 studies testing Sodium Bicarbonate in Acute Kidney Injury are open now, in 3 countries. Recruiting first, the newest first:
Universität Münster · Sites in Germany
Ages 18+
Hospital General de Mexicali · Sites in Mexico
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Sodium Bicarbonate: first FDA approval 1981 (BSS PLUS). What it is approved for, and how studies give it, is on its page →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 112 across the 18 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Arizona State University is the lead sponsor of 239 studies on the registry; 43 are open to participants now.
Arizona State University has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Sodium Bicarbonate in Acute Kidney Injury, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to understand how participating in the Western States Endurance Run (WSER), a 100-mile ultramarathon, affects kidney health. Long, strenuous exercise in hot conditions can temporarily strain the kidneys, especially when combined with dehydration, muscle breakdown, and the use of common pain-relief medications such as ibuprofen. Although kidney stress has been reported in endurance sports, no study has examined it directly in runners during the WSER using newer, more sensitive urine markers of kidney injury. Runners who volunteer will complete brief assessments before and after the race. These include providing a urine sample, a small finger-prick blood sample, a body-weight measurement, and answering a short questionnaire about pain-medication use. During the race, participants will wear a global positioning system (GPS) watch and heart-rate strap to monitor effort. Each assessment takes about 15 minutes, and no follow-up is required. Findings from this study will help determine how often kidney stress occurs in this event and what factors may contribute to it, ultimately supporting safer training and medical practices for ultramarathon athletes.
The study is a single-group, pre- and post-test design where participants will be assessed prior to the start of the WSER, upon completion of the race and 24 hours post-race. Approximately one hour prior to the race commencing, participants will be asked to void the entire contents of their bladder in a urine container in order to measure urine volume, flow rate and urine specific gravity (USG) to assess hydration status and for subsequent analysis of acute kidney injury (AKI) risk (insulin-like growth factor-binding protein 7 (IGFBP7), tissue inhibitor of metalloproteinase 2 (TIMP-2), and neutrophil gelatinase-associated lipocalin (NGAL)). Participants will also be provided a Garmin 945 GPS watch and a wearable device (i.e., the HRM-PRO Run Dynamics strap) for the race. The system is a waterproof heartrate monitor strap with an embedded accelerometer that quantifies gait metrics (ground reaction force). At this time they will also have their weight measured, and complete a short questionnaire to document any recent intake of non-steroidal anti-inflammatory (NSAIDS) medication. Lastly, the research team will collect a small capillary sample (\~ 300 microliters) of whole blood into a heparinised tube and immediately analyse the sample for creatinine (CR) and blood urea nitrogen (BUN) using a portable, point of care analyzer (i-STAT 1 Wireless, Abbott, Princeton).
Upon completing the WSER, participants will again be asked to provide a urine sample (following the pre-race methodology), have their weight measured, complete the questionnaire regarding additional NSAID use during the race, and lastly a final capillary blood sample for post-race analysis of CR and BUN. Participants will then be randomized into one of two groups (sodium bicarbonate (SB) or placebo), with one receiving a pre-packaged standard amount of either 15, 19, or 22 grams of sodium bicarbonate provided by Maurten (Maurten Bicarb System, MaurtenTM, Göteborg, SWE) depending on their body weight. MaurtenTM will also provide an equivalent placebo product. Participants will be asked to consume the SB or placebo, which is delivered in a patented hydrogel system (similar to a yogurt). The urine and blood sampling procedure will be repeated 24 hours post-race at a location to be determined.
All urine samples will be packed in an appropriately labeled biohazard container with cold packs, and brought back to the Arizona State University's Integrated Human Performance Lab (IHPL; Principle Investigator (PI)-Siegler) for measures of AKI risk with the research team. As per the Transportation Security Administration (TSA) regulations, biological specimens that are non-infectious and contain less than 30 mL of fluid in each container are permissible in checked baggage. The samples from each of the 3 races will be approximately 5 milliliters (mL) each subject (so estimated at 50 mL total for each of the 3 races).
Methodological Techniques \& Measurements:
Anthropometric Assessments (Descriptive Data) Participants will be asked to use the restroom to empty their bladder (this sample will be used for AKI biomarkers, urine volume and USG), after which measurements of height and body mass will be obtained. This measurement will occur pre- and post-race to estimate loss of body weight (e.g., dehydration).
Urine Volume and Specific Gravity (USG) Participants will be asked to void into graduated measuring containers (\~ 900 mL), which will subsequently be used to calculate total urine volume pre-, post-race, and 24 hours post-race and normalize AKI markers. Once volume is obtained, samples from this measurement will be used to assess dehydration (USG) and for subsequent analysis of AKI (see Kidney Injury Markers). USG will be measured using a handheld refractometer (Atago PALTMSeries, Tokyo, JP).
Capillary Blood Draws Capillary blood (\~ 300 microliters; 600 total) will be obtained from an index finger pre-, post-race and 24 hours post-race to measure creatinine (CR) and blood urea nitrogen (BUN) using a portable, point of care analyzer (i-STAT 1 Wireless, Abbott, Princeton).
Kidney Injury Markers AKI risk will be assessed using Enzyme-Linked Immunosorbent Assay (ELISA) kits to measure concentrations of insulin-like growth factor-binding protein 7 (IGFBP7) (RayBiotech Life, Peachtree Corners, GA), tissue inhibitor of metalloproteinase 2 (TIMP-2) (RayBiotech Life, Peachtree Corners, GA), and neutrophil gelatinase-associated lipocalin (NGAL) (Enzo Life Sciences, Farmingdale, NY). Urine samples will be centrifuged before analysis and resultant supernatant used for analyses. The kidney markers will be normalized to urine flow rate, considering changes in the urine production that may happen in dehydration conditions such as exercise in the heat. All ELISA analyses will be completed according to manufacturer guidelines.
Heart Rate and Activity Profile Participants will wear a chest-mounted heart rate monitor (Garmin HRM-PRO Run Dynamics strap) during the race. The device consists of an elastic strap with an embedded sensor that is worn directly against the skin, positioned horizontally around the chest, just below the pectoral muscles (breastbone), in accordance with manufacturer instructions. Prior to the race, a trained member of the research team will demonstrate proper placement and fit of the heart rate strap. Participants will be instructed to ensure the strap fits snugly but comfortably, allowing normal breathing and movement without excessive tightness. The strap does not deliver electrical stimulation or vibration; it passively records heart rate and movement data. Participants may adjust or remove the heart rate strap at any time during the race if they experience discomfort, skin irritation, or any other concern. Removal of the strap will not affect continued participation in the study or result in penalty. Heart rate (HR) and activity rates (via accelerometer measurements) will be measured continuously (1 hertz (Hz)) during the race with participants wearing a Garmin 945 GPS watch and a wearable device (i.e., the HRM-PRO Run Dynamics strap).
NSAID Questionnaire During the pre-race data collection period, participants will be asked if they have consumed any non-steroidal anti-inflammatory drugs prior to the start of the race (quantity and type (e.g., ibuprofen)). Once the race is completed, the same questionnaire will be used to ask participants if they consumed any NSAIDs during the race, and at what quantity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
volunteers will be provided 0.3g/kg body weight of sodium bicarbonate to be consumed after completing the Western States Endurance Run (100 miles)
Dietary Supplement: Sodium Bicarbonate (NaHCO3)
volunteers will be provide 0.3g/kg body weight of placebo (corn starch) to be consumed after the race.
Dietary Supplement: Placebo
SB will be used to investigate whether adding a buffer exogenously to aid recovery helps in reducing the severity of acute kidney injury.
The placebo product consists of the same sodium concentration as the intervention group receiving sodium bicarbonate.
tissue inhibitor of metalloproteinase 2 (TIMP-2)
urine biomarkers of acute kidney injury
Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
neutrophil gelatinase-associated lipocalin (NGAL)
urine biomarkers of acute kidney injury
Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
Cystatin C
urine biomarkers of acute kidney injury
Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Aug 2028, 25 months after the start.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 25 months is close to that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Bicarbonate